Weiyuan

Established in 2023 and based in Hangzhou, China, Weiyuan operates as a synthetic biology service company that provides synthetic biology service. The company has an R&D center and pilot site in the field of synthetic biology. The CEO as well as the founder, Wu Yan, graduated from Zhejiang University, and the CTO, Luo Zhibo, graduated from Tsinghua University and Melbourne University. It was awarded as innovative small and medium-sized enterprises in Zhejiang Province.

Some enterprises, such as Sinopep, Titan Purchase Contract, and Huadong Medicine, have cooperated with the company. In April 2025, Weiyuan raised a venture funding from Zhenshi Capital. In March 2026, Weiyuan raised CNY 300 million in series A funding from new investor He'nan Investment Group. Weiyuan uses high-throughput screening platform for engineered strains and AI evolution platform for industrialized enzymes to provide enzyme evolution, peptide industrialization, functional protein customization and nucleotide modification services.

The company's products include active biologics and chiral chemicals. The company generates revenue by offering enzyme evolution, peptide industrialization, functional protein customization and nucleotide modification services. The new financing will be used to strengthen the AI-driven intelligent technology platform and accelerate the construction of key fermentation production pilot bases.